AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02023580 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video treatments
Description: The treatment video vignettes to be delivered between Baseline and 3 Months include: 1) Condom use/anal sex without HIV status disclosure (potentially SDCAS); 2) Condom use/anal sex without HIV status disclosure and perceived responsibility; 3) Discussion of nondisclosure of HIV status prior to sex and perceived responsibility, STIs; 4) Stigma associated with disclosing HIV status to sex partners; 5) HIV/STI testing; and 6) Diagnosis of an STI; STI disclosure to sex partners and perceived responsibility.~Video boosters to be delivered weekly for 4 weeks between 6 and 9 Months include: 7) HIV status disclosure, condom use, STIs; 8) STI disclosure to sex partners, disclosure to friends, serodiscordant partnerships; 9 \& 10) Support of HIV disclosure and perceived responsibility.
Study NCT02023580 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video treatments
Description: The treatment video vignettes to be delivered between Baseline and 3 Months include: 1) Condom use/anal sex without HIV status disclosure (potentially SDCAS); 2) Condom use/anal sex without HIV status disclosure and perceived responsibility; 3) Discussion of nondisclosure of HIV status prior to sex and perceived responsibility, STIs; 4) Stigma associated with disclosing HIV status to sex partners; 5) HIV/STI testing; and 6) Diagnosis of an STI; STI disclosure to sex partners and perceived responsibility.~Video boosters to be delivered weekly for 4 weeks between 6 and 9 Months include: 7) HIV status disclosure, condom use, STIs; 8) STI disclosure to sex partners, disclosure to friends, serodiscordant partnerships; 9 \& 10) Support of HIV disclosure and perceived responsibility.
Study NCT01734785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin
Description: tablet
Study NCT01734785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin + Linagliptin
Description: Fixed dose combination.
Study NCT01734785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin + Linagliptin
Description: Fixed dose combination
Study NCT01734785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin placebo + Linagliptin placebo
Description: Matching Empagliflozin + Linagliptin low dose
Study NCT03935789 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BLAST
Description: 12-week self-guided intervention using a web-based platform
Study NCT02152475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mouthwash with curcumin
Description: Mouthwash with 20 ml of curcumin solution for 5 minutes
Study NCT02152475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mouthwash with curcumin
Description: Mouthwash with 20 ml of curcumin solution for 5 minutes
Study NCT02807532 — intervention group
Intervention type: OTHER
Intervention: atrial fibrillation
Description: In the case-control trial, patients with atrial fibrillation 7 days after surgery will be assigned to an atrial fibrillation group.
Study NCT02807532 — intervention group
Intervention type: OTHER
Intervention: non-atrial fibrillation
Description: In the case-control trial, patients without atrial fibrillation 7 days after surgery will be assigned to a non-atrial fibrillation group.
Study NCT02455232 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: upper limb muscle block
Study NCT02455232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4cc of lidocaïne®
Study NCT00825591 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Oral administration before bed. We will test two doses (0.5 or 3.0 mg/m2. 6 week duration.)
Study NCT00825591 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Oral administration before bed. 6 week duration.
Study NCT03766581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986177
Description: Oral administration
Study NCT03766191 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Food Ads
Description: Exposure to foods ads embedded in an age-appropriate TV program
Study NCT03766191 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Non-food Ads
Description: Exposure to non-food ads embedded in an age-appropriate TV program
Study NCT04069416 — intervention group
Intervention type: PROCEDURE
Intervention: living donor liver transplantation
Description: liver graft from a living donor
Study NCT02844439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesevatinib
Study NCT03450460 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer support
Description: The Program matches volunteer Mentors and Partners for a series of one-to-one interactions that focus on the discussion and resolution of problems or issues (i.e., problem solving) related to one or several key topic areas including family and friends, resources, life changes or challenges, (health care) professionals, social/recreational activities, work/employment/training/volunteering, the brain injury itself, emotions or feelings, and other issues.27 Once the match is established, the Mentor and Partner communicate with one another primarily by telephone until the problems or issues are either resolved or a referral to another service is made (i.e., counselling or community support services). For some partnerships, communication by email or video conferencing is used.27 Most telephone calls last between 20 and 40 minutes (personal communication) and are held weekly.
Study NCT01638000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: oral tablet
Study NCT01638000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin succinate
Description: oral tablet
Study NCT01315340 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ocular rigidity, outflow facility and intraocular pressure measurement
Description: The measurement procedure includes cannulation of the anterior chamber of the eye, under sterile conditions. Infusion of the eye with microvolumes of a saline solution is performed, followed by manometric measurement of intraocular pressure, in order to quantify ocular rigidity. Outflow facility is estimated from recordings of intraocular pressure after the infusion is stopped.
Study NCT01315340 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ocular rigidity, outflow facility and intraocular pressure measurement
Description: The measurement procedure includes cannulation of the anterior chamber of the eye, under sterile conditions. Infusion of the eye with microvolumes of a saline solution is performed, followed by manometric measurement of intraocular pressure, in order to quantify ocular rigidity. Outflow facility is estimated from recordings of intraocular pressure after the infusion is stopped.
Study NCT00939094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2066
Description: Capsule, once daily
Study NCT00939094 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule, once daily
Study NCT01758640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Low dose warfarin of 5mg or less per day
Study NCT02152475 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: blue LED illumination
Description: Oral cavity was illuminated with blue light for 5 minutes
Study NCT02152475 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: blue LED illumination
Description: Oral cavity was illuminated with blue light for 5 minutes
Study NCT03766581 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Administration
Study NCT01162954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-6034
Study NCT01162954 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02468531 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: oxygen
Description: 50% oxygen inhalation
Study NCT02468531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenon
Description: 50% Xenon inhalation
Study NCT03766581 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clopidogrel
Description: Oral administration
Study NCT03766581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Oral administration
Study NCT00239993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glatiramer acetate
Study NCT03766581 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: Oral administration
Study NCT00239993 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Warm compress prior to injection of glatiramer acetate
Study NCT01308814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: Transdermal 17β-estradiol (100 ug/day) for 12 months, administered as patches to be worn continuously and replaced once a week. Also, every 2 months, oral micronized progesterone (200 mg/day x 12 days) will be administered.
Study NCT01308814 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo patches for 12 months, to be worn continuously and replaced once a week. Also, placebo pills will be administered for 12 days every 2 months.
Study NCT01827436 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy
Study NCT01827436 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Asymmetrical gait training
Study NCT01193634 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR 9250 / DR 9550 / CRT 9750
Description: Active implantable defibrillators range
Study NCT01230996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Each patient will also receive chemotherapy with a drug called cisplatin, which is given intravenously through a drip in the arm once a week during their 6 week radiotherapy treatment. Again this is standard treatment for any patient with cervix cancer.
Study NCT01230996 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy
Description: Patients in this trial will receive radiotherapy to the pelvic area with additional chemotherapy (chemoradiotherapy). This is the standard treatment for cervix cancer and will be almost identical to patients not taking part in this study. As patients in the study will be treated with IMRT, the total radiation dose will be slightly higher but without increasing the dose to normal tissue in the pelvis. This will mean the number of radiotherapy treatments that each patient receives in the study is between 27 and 30 compared with the usual 28. Each patient will undergo 6 weeks of radiotherapy treatment and must attend the radiotherapy department hospital once daily (Monday to Friday) over 6 weeks. Each treatment lasts for approximately 10 15 minutes. This is exactly the same as standard practice if patients were not participating in the trial.
Study NCT01230996 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracavitary brachytherapy
Description: Intracavitary brachytherapy Intracavitary brachytherapy will be given towards the end of external beam radiotherapy usually weeks five and six. This is routine treatment and will be given according to local practice As is the convention patients will be reviewed weekly (more frequently if necessary) by their study doctor and will have weekly blood tests to measure full blood count and urea and electrolytes.
Study NCT02876237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: geriatric assessment and quality of life
Description: Included patient must have a geriatric assessment before radiotherapy and 6 months later. This standardized geriatric assessment will collect social information, functional, sensory, cognitive, emotional, motor, nutritional, and medical related to comorbidities .~Patient must complete quality of life questionnaire before radiotherapy then 2 and 6 months later.
Study NCT02876237 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: standard radiotherapy
Study NCT02058316 — intervention group
Intervention type: DEVICE
Intervention: Lateral Flow Device Test
Description: Testing of leftover BAL samples from clinical routine by the lateral flow device test
Study NCT02483923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultrasound guided serratus anterior block with ropivacaine
Description: After induction of anesthesia, patients take ultrasound guided serratus anterior plane block with 0.5ml/kg of ropivacaine 0.375%. 30minutes before the end of operation, intravenous patient controlled analgesia (Basal rate 0ml/hr, 0.5mcg/kg of fentanyl, lock-out time 10minutes) is connected to patient.
Study NCT02483923 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intravenous PCA only
Description: same dose of intravenous patient controlled analgesia (Basal rate 0ml/hr, 0.5mcg/kg of fentanyl, lock-out time 10minutes) is connected to patient only.
Study NCT02572505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada
Description: Female patient will take Truvada and use condoms for each act of intercourse except once at the optimal time for fertility.
Study NCT02882061 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic spinal manipulation
Description: The most hypomobile (stiff) and/or painful segment between T1-T4 will be determined , and this is the segment to which the examiner will apply the thrust. The manipulation will be performed with subjects lying supine. The examiner will use a 'pistol grip' to apply pressure on the articular pillars of the thoracic segment bilaterally in order to block the inferior vertebrae of the hypomobile segment. The subject will cross their arms over their chest to the point where the elbows are aligned. This will allow the examiner to apply pressure through both elbows in an anterior-to-posterior direction. The examiner will assure the direction of force is felt into his/her stabilizing hand. The subject will be asked to take a deep breath in and then exhale completely. A grade V (HVLA) thrust will be applied at the end of the subject's exhalation. If a cavitation is not heard or felt by either the subject or examiner, a second thrust will be performed.
Study NCT02882061 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic spinal manipulation
Description: The most hypomobile (stiff) and/or painful segment between T1-T4 will be determined , and this is the segment to which the examiner will apply the thrust. The manipulation will be performed with subjects lying supine. The examiner will use a 'pistol grip' to apply pressure on the articular pillars of the thoracic segment bilaterally in order to block the inferior vertebrae of the hypomobile segment. The subject will cross their arms over their chest to the point where the elbows are aligned. This will allow the examiner to apply pressure through both elbows in an anterior-to-posterior direction. The examiner will assure the direction of force is felt into his/her stabilizing hand. The subject will be asked to take a deep breath in and then exhale completely. A grade V (HVLA) thrust will be applied at the end of the subject's exhalation. If a cavitation is not heard or felt by either the subject or examiner, a second thrust will be performed.
Study NCT00669825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALV003
Description: Doses via intragastric tube at dosages of either 100 mg, 300 mg, 900 mg, or 1800 mg
Study NCT00669825 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to be administered via intragastric tube
Study NCT00606541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Description: This is an investigator-initiated, single site study, consisting of two phases: 1) 8-week, open label treatment with quetiapine XR (50-400 mg/day) in subjects (n=55 in order to randomize 20 into each of the quetiapine XR and PBO arms in the 2nd phase of the study) with SAD; and 2) in those who demonstrate at least minimal improvement (i.e. CGI≤3), 12-weeks randomized, double-blind treatment with either quetiapine XR or placebo (PBO).
Study NCT00606541 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02426567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exclusive Enteral Nutrition (EEN)
Description: One week course of an isocaloric exclusive milk-based diet
Study NCT01758640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phenindione
Description: Phenindione of 100mg or less per day
Study NCT02426567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Crohn's Disease TReatment-with-EATing diet (CD-TREAT diet)
Description: One week course of an isocaloric, exclusion food-based diet
Study NCT04717544 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention Arm
Description: The smoking cessation intervention will include 1) a six-week, 60-75 minute weekly cognitive-behavioral therapy (CBT) smoking cessation counseling group; and 2) smoking cessation medication include varenicline (Chantix), bupropion (Zyban) and nicotine replacement therapy (NRT). Dispensing these medications will include a 15-minute medication management visit with a prescribing clinician. Clients will choose their own preferred treatment. The standard prescription for NRT will include a transdermal patch at a dose that approximates for current average mg of nicotine intake and nicotine gums or lozenges (in either 2 mg or 4 mg strengths). Prescription for varenicline will be 0.5 mg once daily for three days, then 0.5 mg twice daily for the next four days, then 1 mg twice daily thereafter. Absent any contraindications to the drugs listed above, bupropion (Zyban) 150mg will be offered and prescribed once daily for one week, following by bupropion 300 mg once daily thereafter.
Study NCT01685242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-170 0.24%
Description: 1 drop in each eye at 2 separate times during a 14 day period
Study NCT01685242 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AC-170 0%
Description: 1 drop in each eye at 2 separate times during a 14 day period
Study NCT01391169 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: seromuscular flap enforcement
Description: seromuscular flap enforcement
Study NCT01391169 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: seromuscular flap enforcement
Description: seromuscular flap enforcement
Study NCT04060069 — intervention group
Intervention type: OTHER
Intervention: Ringer Lactate
Description: Fluids
Study NCT03269916 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anti Mueller hormone
Description: used to assess ovarian reserve parameters
Study NCT03269916 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Anti Mueller hormone
Description: used to assess ovarian reserve parameters
Study NCT03269916 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Estrogen
Description: used to assess ovarian reserve parameters
Study NCT03269916 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Estrogen
Description: used to assess ovarian reserve parameters
Study NCT03269916 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follicle-Stimulating Hormone
Description: used to assess ovarian reserve parameters
Study NCT03269916 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Follicle-Stimulating Hormone
Description: used to assess ovarian reserve parameters
Study NCT03269916 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antral alveolar cell count
Description: used to assess ovarian reserve parameters
Study NCT03269916 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Antral alveolar cell count
Description: used to assess ovarian reserve parameters
Study NCT04615234 — intervention group
Intervention type: DEVICE
Intervention: Pharmacogenomics test (PGx)
Description: The clinicians of the TGTG group patients receive the PGx test report within 48 hours and all the participants start the new treatment within 72 hours. According with both Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG) guidelines, the PGx report places the most ADs widespread in Italy, into three recommended categories: 1) use as directed (labelled as Green), 2) use with caution (labelled as Yellow), 3) use with extreme caution (labelled as Red)
Study NCT02603237 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Glucose tolerance test
Description: Standardized oral glucose tolerance test (75 g oral glucose) and blood collection before and 2hrs after the glucose load
Study NCT02603237 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Fat tolerance test
Description: Oral fat tolerance will be provided to fasting participants and blood samples will be collected before and 4 hrs after the fat load.
Study NCT05360693 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immediate implant placement without bone grafting
Description: After atraumatic extraction of the non-restorable tooth using periotome and luxators, osteotomy site preparation will be done \& patients will receive an immediate post-extraction implant without any grafting material in the socket between the residual labial bone and implant surface. After implant insertion, the labial bone dimensions of the buccal peri-implant defect will be measured using Automated Voxel Superimposition Method of CBCT scans. All the patients in this study had two scans; primary (preoperative) scan and secondary (Postoperative) scan, with standardization of the exposure parameters. All datafrom CBCT examinations were acquired in a DICOM format which were imported to OnDemand3D ®App software (Cybermed, Seoul, Korea). superimposition of DICOM sets of each patient using Fusion module of Ondemand 3D App software was done.